Miller has represented Mr. Streck across all of his whistleblowing cases. The Department of Justice announced the settlement agreements regarding Streck's previous claims with Bristol Myers Squibb in 2021, Astellas Pharma and Amgen in 2019 and with AstraZeneca and Cephalon in 2015. In 2018, when the government declined to intervene, Streck and his attorneys proceeded to litigation against Eli Lilly. These efforts include successfully defeating two motions to dismiss in 2018 by defendants Eli Lilly and Astellas Pharma U.S. Today's decision marks the thirteenth previously-declined False Claims Act case that Walden Macht & Haran partner Miller has successfully prosecuted on behalf of the federal and state governments. The case is captioned U.S. ex rel. Ronald Streck et al. v. Takeda Pharmaceuticals America, Inc. No. 1:14-cv-09412 and proceeded in the Northern District of Illinois.